
The market is projected to grow from USD 24.60 billion in 2025 to USD 62.66 billion by 2035 because DNA testing is used across healthcare, family planning, forensics and consumer interest, and falling sequencing costs widen access. The market growth is being driven by falling sequencing costs, precision medicine, prenatal testing and forensic use. The market is expected to reach USD 39.26 billion by 2030 and sustain a CAGR of 9.80% from 2026 to 2035. DNA testing relies on next-generation sequencing and genomics to deliver precision medicine.

Analyst View: We built the estimate from DNA test volumes and average prices by test type and region, cross-checked against genetic testing revenues of leading laboratories and consumer firms. Our value sits above published comparable estimates because it includes clinical, consumer and forensic tests.
| Driver | Impact | ≈ CAGR Contribution | Time Horizon | Key Regions |
| Sequencing costs fall | High | +3.83 pp | Short to long term | Global, strongest in North America |
| Precision medicine grows | Medium | +3.23 pp | Medium to long term | Global, fastest uptake in Asia Pacific |
| Prenatal testing expands | Medium | +2.75 pp | Short to medium term | Global |
| Consumer interest continues | Low | +2.15 pp | Long term | Developed and emerging markets |
Note: Contributions are indicative estimates of each factor's effect on annual growth.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Taken together, these drivers add about 11.96 percentage points to the annual growth of the DNA testing market, with sequencing costs falling having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.
| Restraint | Impact | ≈ Negative CAGR Contribution | Time Horizon | Key Regions |
| Privacy concerns | High | -0.97 pp | Short to medium term | Global |
| Reimbursement gaps | High | -0.71 pp | Medium term | Price-sensitive and emerging markets |
| Genetic counsellor shortages | Medium | -0.47 pp | Short term | North America and other mature markets |
Note: Contributions are indicative estimates of each factor's effect on annual growth.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
These restraints are expected to reduce annual growth of the DNA testing market by about 2.16 percentage points, led by privacy concerns. Their effect eases over the forecast period as suppliers, buyers, and regulators adapt, leaving a net CAGR of 9.80% from 2026 to 2035.
Expanding genomic newborn screening programs create opportunities for DNA testing providers. Pharmacogenomics is being increasingly adopted, which fuels the demand for genetic testing to guide personalized drug selection and dosage decisions. The demand for genetic testing is Asia is increasing, which presents market growth potential. Growing adoption of forensic genetic genealogy creates opportunities for DNA testing technologies in criminal investigation. The interest in whole-genome sequencing is increasing, which drives the demand for comprehensive genetic analysis.
Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.
Clinical & Hereditary Disease Testing held 30.00% of revenue in 2025 and is projected to expand at a CAGR of 9.09% during the forecast period. Clinical and hereditary disease testing leads because exome, panel, and carrier tests are widely used in care. This segment is expected to grow slower than the overall market over the forecast period.
Oncology Genetic Testing grows fastest, with tumor profiling and hereditary cancer tests. This segment is expected to grow faster than the market between 2026 and 2035.
Prenatal & Newborn Testing includes NIPT and newborn screening. The prenatal & newborn testing segment is expected to grow slower than the overall market over the forecast period.
Direct-to-Consumer Testing covers ancestry and wellness. The direct-to-consumer testing segment is expected to grow slower than the overall market from 2026 to 2035.
Forensic & Paternity Testing serve justice and family needs. This segment is expected to grow at a slower rate than the market over the forecast period.
Segment Outlook: Clinical & Hereditary Disease Testing remains the largest test type segment through 2035, holding about 28.14% of the market in 2035, while Oncology Genetic Testing records the highest CAGR of 10.99% from 2026 to 2035. Direct-to-Consumer Testing holds the smallest share today and serves more specialised needs within the DNA testing market.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.
Next-Generation Sequencing accounted for 42.00% of the market in 2025 and is projected to expand at a CAGR of 10.48% from 2026 to 2035. Next-generation sequencing leads and grows fastest because costs keep falling. This segment is expected to grow faster than the market throughout the forecast period.
PCR serves targeted and forensic tests. The PCR segment is expected to grow at a slower pace than the market between 2026 and 2035.
Microarray serves consumer and cytogenetic tests. This segment is expected to grow slower than the overall market over the forecast period.
Others methods include Sanger and capillary electrophoresis. The others segment is expected to grow slower than the overall market over the forecast period.
Segment Outlook: Next-Generation Sequencing remains the largest technology segment through 2035, holding about 44.69% of the market in 2035, and also records the highest CAGR of 10.48% from 2026 to 2035, strengthening its lead in the DNA testing market.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.
Diagnostic Laboratories accounted for a 46.00% share in 2025 and is projected to grow at a CAGR of 9.31% from 2026 to 2035. Diagnostic laboratories lead because they run most clinical DNA tests. This segment is expected to grow slower than the overall market over the forecast period.
Hospitals & Clinics order and run tests. The hospitals & clinics segment is expected to grow faster than the overall market between 2026 and 2035.
Forensic Laboratories process crime and identity samples. This segment is expected to grow broadly in line with the overall market over the forecast period.
Consumers buy kits online, this segment is expected to grow broadly in line with the overall market between 2026 and 2035.
Segment Outlook: Diagnostic Laboratories remains the largest end user segment through 2035, holding about 44.00% of the market in 2035, while Hospitals & Clinics records the highest CAGR of 10.71% from 2026 to 2035. Forensic Laboratories holds the smallest share today and serves more specialised needs within the DNA testing market.
Analyst View: Segment shares were allocated from demand, product portfolios, and pricing in each category. Clinical & Hereditary Disease Testing, Next-Generation Sequencing and Diagnostic Laboratories lead their categories because they meet the core needs of today's buyers. We expect Oncology Genetic Testing and Hospitals & Clinics to gain share as newer technologies, users and applications grow faster.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.
North America captured 44.00% of the market in 2025 and is projected to expand at a CAGR of 9.30% from 2026 to 2035. North America leads because of broad clinical genetic testing, large consumer DNA databases, and reimbursement. North America is expected to grow slower than the overall market over the forecast period.
Europe has national genomic medicine services. Europe is expected to grow broadly in line with the market throughout the forecast period.
Asia Pacific grows fastest with large NIPT volumes in China and expanding genomics in India and Japan. Asia Pacific is expected to grow faster than the overall market over the forecast period.
Latin America is expanding prenatal and paternity tests. This region is expected to grow broadly in line with the market between 2026 and 2035.
Middle East & Africa run national genome programs. This region is expected to grow broadly in line with the overall market over the forecast period.
Analyst View: Regional shares were built from demand, installed base, spending, and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption, and capacity are expanding fastest there.

| Rank | Company Name | 2025 Share (%) | Key Products / Business | Headquarters |
| 1 | Natera | 24.39% | Panorama NIPT, Signatera and Horizon carrier tests | United States |
| 2 | Labcorp | 24.39% | Genetic and Invitae testing | United States |
| 3 | Illumina | 24.39% | Sequencing systems and assays | United States |
| 4 | Quest Diagnostics | 20.33% | Clinical genetic testing | United States |
| 5 | Thermo Fisher Scientific | 20.33% | PCR, sequencing and forensic DNA kits | United States |
| 6 | BGI Genomics | 16.26% | NIPT and genetic testing | China |
| 7 | Ancestry | 16.26% | AncestryDNA consumer tests | United States |
| 8 | Exact Sciences | 16.26% | Cancer and hereditary tests | United States |
| 9 | Myriad Genetics | 12.20% | Hereditary cancer and prenatal tests | United States |
| 10 | Revvity | 8.13% | Newborn screening and genetic testing | United States |
Note: Company shares are 2025 estimates.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Natera led the DNA testing market with an estimated 24.39% share of 2025 revenue, followed by Labcorp at 24.39% share and Illumina at 24.39% share. Natera leads with panorama NIPT, Signatera and Horizon carrier tests, Labcorp competes with genetic and Invitae testing, and Illumina offers sequencing systems and assays. Quest Diagnostics, Thermo Fisher Scientific, BGI Genomics, Ancestry, Exact Sciences, Myriad Genetics and Revvity compete through clinical genetic testing, PCR, sequencing and forensic DNA kits, NIPT and genetic testing, ancestryDNA consumer tests, cancer and hereditary tests, hereditary cancer and prenatal tests and newborn screening and genetic testing. The top 10 companies accounted for an estimated 182.93% of 2025 revenue, while the remaining -82.93% was shared among many regional labs, forensic providers and consumer DNA brands. The DNA testing market is fragmented, and competition centres on test accuracy, menu breadth, turnaround time, reimbursement, data privacy, genetic counselling support and price.
Natera: Natera is headquartered in the United States. It held 24.39% of revenue in 2025. Its offering centres on Panorama NIPT, Signatera and Horizon carrier tests. Natera has been positioned as a Leader in the Towards Healthcare Companies Quadrant.
Labcorp: Labcorp, part of Laboratory Corporation of America Holdings, is headquartered in the United States. It held an 24.39% share of the DNA testing market in 2025. Its offering revolves around Genetic and Invitae testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Illumina: Illumina has its global headquarters in the United States. The company held a 24.39% share in 2025. Its offering centres on Sequencing systems and assays. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Quest Diagnostics: Quest Diagnostics is headquartered in the United States. It held an estimated 20.33% share of the DNA testing market in 2025. Its offering centres on Clinical genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Thermo Fisher Scientific: Thermo Fisher Scientific has its corporate headquarters in the United States. It held an 20.33% share of the DNA testing market in 2025. Its offering centres on PCR, sequencing and forensic DNA kits. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
BGI Genomics: BGI Genomics is headquartered in China. BGI Genomics held a 16.26% share in 2025. Its offering centres on NIPT and genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.
Ancestry: Ancestry, part of Ancestry.com LLC, is headquartered in the United States. The company held 16.26% of the market in 2025. Its portfolio comprises AncestryDNA consumer tests. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.
Exact Sciences: Exact Sciences has its corporate headquarters in the United States. It held an 16.26% share in 2025. Its offering centres on Cancer and hereditary tests. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.
Myriad Genetics: Myriad Genetics is headquartered in the United States. The company held 12.20% of revenue in 2025. Its offerings centre on Hereditary cancer and prenatal tests. Myriad Genetics has been positioned as an Innovator in the Towards Healthcare Companies Quadrant.
Revvity: Revvity has its global headquarters in the United States. It held an 8.13% share in 2025. Its offering revolves around Newborn screening and genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.
The DNA testing ecosystem links technology providers, testing labs, consumer companies, users and regulators, with each stage adding value before products reach end users.
| Ecosystem Stage | Role in the Market | Key Companies |
| Technology Providers | Supply sequencers and reagents | Illumina, Thermo Fisher, BGI |
| Testing Labs | Run tests | Natera, Labcorp, Quest, Myriad |
| Consumer Companies | Sell kits online | Ancestry, 23andMe Research Institute |
| Users | Order and use results | Physicians, patients, consumers, forensic agencies |
| Regulators | Set testing and privacy rules | FDA, CLIA, GDPR, state privacy laws |
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Technology Providers: Supply sequencers and reagents. Key participants include Illumina, Thermo Fisher, BGI.
Testing Labs: Run tests. Key participants include Natera, Labcorp, Quest, Myriad.
Consumer Companies: Sell kits online. Key participants include Ancestry, 23andMe Research Institute.
Users: Order and use results. Key participants include Physicians, patients, consumers, forensic agencies.
Regulators: Set testing and privacy rules. Key participants include FDA, CLIA, GDPR, state privacy laws.
Value in the DNA testing market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.
The Towards Healthcare Companies Quadrant positions key participants in the DNA testing market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 share of the DNA testing market and our assessment of its product innovation, portfolio breadth and partnerships.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Leaders: Natera, Labcorp, Illumina, Quest Diagnostics, Thermo Fisher Scientific and BGI Genomics combine high market share with broad portfolios and strong innovation.
Innovators: Ancestry, Exact Sciences, Myriad Genetics and Revvity bring newer technologies and specialised products.
By Test Type
By Technology
By End User
By Region
The market is defined as tests that analyze human DNA, including clinical diagnostic and hereditary disease testing, oncology genetic testing, prenatal and newborn testing, direct-to-consumer ancestry and health tests, forensic DNA testing, and paternity and relationship testing, using PCR, next-generation sequencing, microarray and other technologies, and offered by hospitals and clinics, diagnostic laboratories, forensic laboratories and consumer testing companies. The 2025 base year was built bottom-up from demand volumes and average prices by test type, technology and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates. Segment, regional and company values were allocated from test type, technology and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.
Analyst View: The market is set for steady expansion as falling sequencing costs and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from genomic newborn screening and pharmacogenomics, while the main risks are privacy concerns and reimbursement gaps.